Forge Biologics, a Gene Therapy-focused contract development and manufacturing organization (CDMO), said that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease. PRIME is a regulatory designation by the EMA that provides early and […]

The post Forge Biologics Receives PRIME Designation from EMA for Novel Gene Therapy first appeared on World Pharma Today.